Cancer is known to be one of the leading causes of deaths worldwide. In fact, as per the WHO, close to 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems. Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Given the limitations associated with conventional cancer treatment options, there has been a surge in the need for more effective, safe and versatile alternatives, such as TIL-based therapies.
TIL Therapies – Current Market Landscape
The TIL therapies landscape features, close to 30 industry players, across the globe claim to be actively evaluating TIL therapies to treat advance, incurable oncological disorders. The contemporary TIL therapies market is characterized by a healthy and growing pipeline of more than 75 candidate therapies. More than 95% of the therapy candidates, which are being developed to target a wide range of disease indications are autologous in nature.
TIL Therapies – Partnerships and Collaborations
A growing interest in this field is reflected from the increase in the partnerships focused on R&D, representing close to 40% of the total partnerships, involving both international and indigenous stakeholders. This is followed by licensing deals; most of the licensing deals are focused on the licensing of TIL technologies. Majority of such deals were signed between players based in North America.
TIL-based Therapies – Funding and Investments
Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 2.7 billion, across 30 instances, since 2013. Specifically, in last three years, industry players raised over USD 1.4 billion for the development of these therapies. In addition, majority (37%) of the companies primarily received funding through secondary offering. Further, close to 85% of the total funding instances were reported by players headquartered in the US.
TIL Therapies – Patent Analysis
Majority of the patents in this domain are patent applications (72%), followed by granted patents (28%). In addition, most of the patents (60%) were filed / granted in North America. This is followed by patents filed / granted in Europe.
TIL Therapies – Market Forecast and Opportunity Analysis
In the long-term, the overall projected opportunity is likely to be well distributed across key market segments, including target indications, key players and geographical regions; the market is expected to grow at a CAGR of ~40% by 2035.
Owing to their tumor-killing capability and therapeutic superiority, TIL therapies are being actively evaluated to treat advance, incurable oncological disorders by various researchers and industry stakeholders. Moreover, the ongoing research activity in this field has led to the discovery of several novel molecular targets, further strengthening the research pipelines of companies engaged in this market. Several clinical trials have proven the efficacy of TIL-based therapies, presenting lucrative opportunities for the players engaged in the development of these products. Driven by a promising development pipeline and encouraging clinical trial results, the TIL-based therapy market is likely to carve out a significant share of the multi-billion-dollar cancer immunotherapy market.